Novo Nordisk receives US FDA approval for Xultophy 100/3.6

Novo Nordisk announced that the US FDA has approved the NDA for Xultophy® 100/3.6.Xultophy® 100/3.6 is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin or liraglutide.

Xultophy® 100/3.6, the approved brand name for IDegLira in the US, is a once-daily, single injection fixed combination of long-acting insulin degludec (Tresiba®) and the GLP-1 analogue liraglutide (Victoza®). In the DUAL phase 3 clinical trial programme, Xultophy® 100/3.6 consistently showed an improvement of glycaemic control in adults with type 2 diabetes uncontrolled on liraglutide or basal insulin therapy. For adults inadequately controlled on insulin glargine U100, treatment with Xultophy® 100/3.6 demonstrated a reduction in HbA1c of 1.7% after 26 weeks. Xultophy® 100/3.6 can be taken at the same time each day with or without food and will be available in a prefilled pen.

“We are pleased with the approval of Xultophy® 100/3.6 and look forward to launching it in the US in the first half of 2017”, said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “We believe Xultophy® 100/3.6 offers significant benefits and is an important and convenient treatment option especially for people not achieving sufficient glycaemic control with basal insulin”.

The approval follows the recommendation of the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC), which voted 16-0 in favour of an approval of Xultophy® 100/3.6 for the treatment of adults with type 2 diabetes, at its meeting on 24 May 2016.

About Xultophy® 100/3.6Xultophy® 100/3.6 is a once-daily, single injection fixed combination of long-acting insulin degludec (Tresiba®) and the GLP-1 analogue liraglutide (Victoza®). The Xultophy® 100/3.6 pen delivers doses from 10 to 50 units with each injection. Each unit of Xultophy® 100/3.6 contains 1 unit of insulin degludec and 0.036 mg of liraglutide.

Media:

Katrine Sperling
+45 3079 6718
krsp@novonordisk.com

Ken Inchausti (US)
+1 609 786 8316
kiau@novonordisk.com

Investors: 

Peter Hugreffe Ankersen
+45 3075 9085
phak@novonordisk.com

Melanie Raouzeos
+45 3075 3479
mrz@novonordisk.com

Hanna Ögren
+45 3079 8519
haoe@novonordisk.com

Anders Mikkelsen
+45 3079 4461
armk@novonordisk.com

Kasper Veje (US)
+1 609 235 8567
kpvj@novonordisk.com